Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.
Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.
复制标题
齐多夫定对血清人类免疫缺陷病毒核心抗原水平的影响。
DOI：
--
复制
发表时间：
1988
影响因子：
--
通讯作者：
P. Volberding
中科院分区：
文献类型：
--
作者：
R. E. Chaisson;M. Leuther;Jean;S. Nusinoff;Gloria S. Boone;David W. Feigal;P. Volberding
我们评估了抗病毒治疗对参加齐多夫定治疗艾滋病（AIDS）及艾滋病相关综合征Ⅱ期试验患者血清人类免疫缺陷病毒核心抗原（HIV - Ag）水平的影响。在入组时，45%的受试者检测到人类免疫缺陷病毒核心抗原（艾滋病患者中为59%，艾滋病相关综合征患者中为37%）。接受齐多夫定治疗的受试者的HIV - Ag中位水平从入组时的111皮克/毫升下降到4周时的46皮克/毫升，而安慰剂接受者的水平没有显著变化。齐多夫定接受者的HIV - Ag下降在16周的治疗过程中持续存在，且与安慰剂组有显著差异。两组的抗p24抗体水平均无变化。我们得出结论，在有HIV抗原血症的患者中，HIV - Ag水平的变化是抗逆转录病毒活性的一个重要标志。
We assessed the effect of antiviral therapy on serum human immunodeficiency virus core antigen (HIV-Ag) levels in patients enrolled in the phase II trial on zidovudine for acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Human immunodeficiency virus core antigen was detected in 45% of subjects at entry (59% with AIDS and 37% of patients with AIDS-related complex). Median HIV-Ag levels in zidovudine-treated subjects fell from 111 pg/mL at entry to 46 pg/mL at four weeks, while levels in placebo recipients did not change significantly. Decline in HIV-Ag in zidovudine recipients was sustained through 16 weeks of treatment and was significantly different from the placebo group. Anti-p24 antibody levels did not change in either group. We conclude that in patients with HIV-antigenemia changes in HIV-Ag level are an important marker of anti-retroviral activity.